Stay updated with breaking news from Adapted. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to
NEW YORK and MAINZ, GERMANY, November 10, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY Original/Omicron BA.4/BA.5
Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years
NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) and German partner BioNTech SE (BNTX) announced Friday updated data from a Phase 2/3 clinical trial for Omicron BA.4/BA.5-adapted bivalent
EMA’s human medicines committee (CHMP) has recommended authorising an adapted Spikevax COVID-19 vaccine targeting the Omicron subvariants BA.4 and...